RaySearch Laboratories AB Class B ( (RSLBF) ) has released its Q3 earnings. Here is a breakdown of the information RaySearch Laboratories AB Class B presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
RaySearch Laboratories AB Class B is a leading provider of innovative software solutions for radiation therapy in the healthcare industry, focusing on cancer treatment. In its latest earnings report for the third quarter of 2024, the company demonstrated robust financial growth with a 16% increase in net sales compared to the same period last year. Key highlights from the quarter include a notable operating profit of SEK 61.8 million, an impressive profit after tax of SEK 45.4 million, and earnings per share before/after dilution rising to SEK 1.32. The company also reported continued expansion in major markets, including significant orders from healthcare centers in the USA, UK, and China. Furthermore, RaySearch launched a new version of its RayStation software, emphasizing automation and efficiency improvements, and appointed Nina Grönberg as the new CFO. Looking forward, RaySearch aims to capitalize on its strong financial position and favorable growth opportunities, with the board raising the operating margin target to at least 25% by 2026.
